NextCure (NASDAQ:NXTC) Major Shareholder Adar1 Capital Management, Llc Buys 3,410 Shares

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc acquired 3,410 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The shares were bought at an average price of $5.00 per share, with a total value of $17,050.00. Following the acquisition, the insider directly owned 393,266 shares in the company, valued at $1,966,330. This represents a 0.87% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Tuesday, July 28th, Adar1 Capital Management, Llc bought 6,400 shares of NextCure stock. The stock was bought at an average price of $4.95 per share, for a total transaction of $31,680.00.
• On Monday, July 27th, Adar1 Capital Management, Llc bought 7,798 shares of NextCure stock. The shares were bought at an average cost of $5.00 per share, for a total transaction of $38,990.00.

NextCure Stock Performance

NextCure stock opened at $5.02 on Thursday. The company has a 50 day moving average price of $3.66 and a 200-day moving average price of $8.77. NextCure, Inc. has a fifty-two week low of $1.55 and a fifty-two week high of $15.74. The company has a market capitalization of $18.12 million, a PE ratio of -0.29 and a beta of 1.42.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.10) by $0.23. On average, analysts forecast that NextCure, Inc. will post -7.89 earnings per share for the current year.

Hedge Funds Weigh In On NextCure

Several institutional investors and hedge funds have recently added to or reduced their stakes in NXTC. Marshall Wace LLP bought a new position in NextCure in the fourth quarter worth about $160,000. Millennium Management LLC purchased a new position in shares of NextCure in the 4th quarter worth approximately $185,000. Geode Capital Management LLC grew its position in shares of NextCure by 18.6% in the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after buying an additional 3,636 shares during the last quarter. Cable Car Capital LP raised its stake in shares of NextCure by 13.1% during the 2nd quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock worth $349,000 after acquiring an additional 88,040 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of NextCure by 18.7% during the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after acquiring an additional 5,300 shares in the last quarter. Hedge funds and other institutional investors own 42.65% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on NXTC. Zacks Research upgraded NextCure from a “strong sell” rating to a “hold” rating in a report on Thursday, June 11th. Wall Street Zen cut shares of NextCure from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Weiss Ratings lowered shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of NextCure in a research report on Wednesday, July 15th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $19.00.

NextCure Company Profile

NextCure, Inc is a clinical?stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large?scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.